Revance Therapeutics, Inc. has won US Food and Drug Administration for Daxxify (daxibotulinumtoxinA-lanm) in the treatment of cervical dystonia (CD) – its second indication overall, but its first therapeutic use. The product, initially approved as an aesthetic medicine to reduce the appearance of glabellar lines, has the potential to best market leader Botox (onabotulinumtoxinA) in CD given its longer-lasting efficacy in a disease where neuromodulator benefits often wear off too soon for retreatment.
[Sidebar#SC147024]
